カテゴリー： QYResearch, 世界

強皮症治療薬の世界市場：規模・現状・予測2019-2025

【英語タイトル】Global Scleroderma Therapeutics Market Size, Status and Forecast 2019-2025

QYResearchが出版した調査資料（DATA909X18941）・商品コード：DATA909X18941
・発行会社（調査会社）：QYResearch
・発行日：2019年11月25日（※2024年版があります。お問い合わせください）
・ページ数：128
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,900 ⇒換算￥577,200見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,850 ⇒換算￥865,800見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,800 ⇒換算￥1,154,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※当調査レポートでは、強皮症治療薬の世界市場について調査・分析し、強皮症治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリンアナログ、カルシウムチャネル遮断薬、鎮痛薬、その他）、用途別（全身、ローカライズ）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。


・レポートの概要
・世界の強皮症治療薬市場動向
・主要企業別マーケットシェア
・強皮症治療薬の種類別市場規模2014-2019
（免疫抑制剤、ホスホジエステラーゼ5阻害剤-PHA、エンドセリン受容体拮抗薬、プロスタサイクリンアナログ、カルシウムチャネル遮断薬、鎮痛薬、その他）
・強皮症治療薬の用途別市場規模2014-2019
（全身、ローカライズ）
・強皮症治療薬の北米市場：主要企業・種類別/用途別市場規模
・強皮症治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模
・強皮症治療薬の中国市場：主要企業・種類別/用途別市場規模
・強皮症治療薬の日本国内市場：主要企業・種類別/用途別市場規模
・強皮症治療薬の東南アジア市場：主要企業・種類別/用途別市場規模
・強皮症治療薬のインド市場：主要企業・種類別/用途別市場規模
・強皮症治療薬の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（F. Hoffmann-La Roche AG、Bristol-Myers Squibb Company、Celgene Corporation、Argentis Pharmaceuticals, LLC、Bayer AG、Boehringer Ingelheim International GmbH、Akashi Therapeutics、Prometic Life Sciences, Inc.、Emerald Health Pharmaceuticals、Kadmon Holdings, Inc.、Seattle Genetics, Inc.、Cytori Therapeutics, Inc.、Fibrocell Science, Inc.、Chemomab、Corbus Pharmaceuticals Holdings, Inc.、Genkyotex）
・強皮症治療薬の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...
【レポートの概要】

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
In 2018, the global Scleroderma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Scleroderma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Scleroderma Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Celgene Corporation
Argentis Pharmaceuticals, LLC
Bayer AG
Boehringer Ingelheim International GmbH
Akashi Therapeutics
Prometic Life Sciences, Inc.
Emerald Health Pharmaceuticals
Kadmon Holdings, Inc.
Seattle Genetics, Inc.
Cytori Therapeutics, Inc.
Fibrocell Science, Inc.
Chemomab
Corbus Pharmaceuticals Holdings, Inc.
Genkyotex

Market segment by Type, the product can be split into
Immunosuppressors
Phosphodiesterase 5 Inhibitors – PHA
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Analgesics
Others

Market segment by Application, split into
Systemic
Localized

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Scleroderma Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Scleroderma Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Scleroderma Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Immunosuppressors
1.4.3 Phosphodiesterase 5 Inhibitors – PHA
1.4.4 Endothelin Receptor Antagonists
1.4.5 Prostacyclin Analogues
1.4.6 Calcium Channel Blockers
1.4.7 Analgesics
1.4.8 Others
1.5 Market by Application
1.5.1 Global Scleroderma Therapeutics Market Share by Application (2019-2025)
1.5.2 Systemic
1.5.3 Localized
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Scleroderma Therapeutics Market Size
2.2 Scleroderma Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Therapeutics Market Size by Regions (2019-2025)
2.2.2 Scleroderma Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Scleroderma Therapeutics Market Size by by Players
3.1.1 Global Scleroderma Therapeutics Revenue by by Players (2014-2019)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by by Players (2014-2019)
3.1.3 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Scleroderma Therapeutics Key Players Head office and Area Served
3.3 Key Players Scleroderma Therapeutics Product/Solution/Service
3.4 Date of Enter into Scleroderma Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Scleroderma Therapeutics Market Size by Type (2014-2019)
4.2 Global Scleroderma Therapeutics Market Size by Application (2014-2019)

5 North America
5.1 North America Scleroderma Therapeutics Market Size (2014-2019)
5.2 Scleroderma Therapeutics Key Players in North America
5.3 North America Scleroderma Therapeutics Market Size by Type
5.4 North America Scleroderma Therapeutics Market Size by Application

6 Europe
6.1 Europe Scleroderma Therapeutics Market Size (2014-2019)
6.2 Scleroderma Therapeutics Key Players in Europe
6.3 Europe Scleroderma Therapeutics Market Size by Type
6.4 Europe Scleroderma Therapeutics Market Size by Application

7 China
7.1 China Scleroderma Therapeutics Market Size (2014-2019)
7.2 Scleroderma Therapeutics Key Players in China
7.3 China Scleroderma Therapeutics Market Size by Type
7.4 China Scleroderma Therapeutics Market Size by Application

8 Japan
8.1 Japan Scleroderma Therapeutics Market Size (2014-2019)
8.2 Scleroderma Therapeutics Key Players in Japan
8.3 Japan Scleroderma Therapeutics Market Size by Type
8.4 Japan Scleroderma Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Scleroderma Therapeutics Market Size (2014-2019)
9.2 Scleroderma Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Scleroderma Therapeutics Market Size by Type
9.4 Southeast Asia Scleroderma Therapeutics Market Size by Application

10 India
10.1 India Scleroderma Therapeutics Market Size (2014-2019)
10.2 Scleroderma Therapeutics Key Players in India
10.3 India Scleroderma Therapeutics Market Size by Type
10.4 India Scleroderma Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Scleroderma Therapeutics Market Size (2014-2019)
11.2 Scleroderma Therapeutics Key Players in Central & South America
11.3 Central & South America Scleroderma Therapeutics Market Size by Type
11.4 Central & South America Scleroderma Therapeutics Market Size by Application

12 International Players Profiles
12.1 F. Hoffmann-La Roche AG
12.1.1 F. Hoffmann-La Roche AG Company Details
12.1.2 Company Description and Business Overview
12.1.3 Scleroderma Therapeutics Introduction
12.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2014-2019))
12.1.5 F. Hoffmann-La Roche AG Recent Development
12.2 Bristol-Myers Squibb Company
12.2.1 Bristol-Myers Squibb Company Company Details
12.2.2 Company Description and Business Overview
12.2.3 Scleroderma Therapeutics Introduction
12.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2014-2019)
12.2.5 Bristol-Myers Squibb Company Recent Development
12.3 Celgene Corporation
12.3.1 Celgene Corporation Company Details
12.3.2 Company Description and Business Overview
12.3.3 Scleroderma Therapeutics Introduction
12.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2014-2019)
12.3.5 Celgene Corporation Recent Development
12.4 Argentis Pharmaceuticals, LLC
12.4.1 Argentis Pharmaceuticals, LLC Company Details
12.4.2 Company Description and Business Overview
12.4.3 Scleroderma Therapeutics Introduction
12.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2014-2019)
12.4.5 Argentis Pharmaceuticals, LLC Recent Development
12.5 Bayer AG
12.5.1 Bayer AG Company Details
12.5.2 Company Description and Business Overview
12.5.3 Scleroderma Therapeutics Introduction
12.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2014-2019)
12.5.5 Bayer AG Recent Development
12.6 Boehringer Ingelheim International GmbH
12.6.1 Boehringer Ingelheim International GmbH Company Details
12.6.2 Company Description and Business Overview
12.6.3 Scleroderma Therapeutics Introduction
12.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2014-2019)
12.6.5 Boehringer Ingelheim International GmbH Recent Development
12.7 Akashi Therapeutics
12.7.1 Akashi Therapeutics Company Details
12.7.2 Company Description and Business Overview
12.7.3 Scleroderma Therapeutics Introduction
12.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2014-2019)
12.7.5 Akashi Therapeutics Recent Development
12.8 Prometic Life Sciences, Inc.
12.8.1 Prometic Life Sciences, Inc. Company Details
12.8.2 Company Description and Business Overview
12.8.3 Scleroderma Therapeutics Introduction
12.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2014-2019)
12.8.5 Prometic Life Sciences, Inc. Recent Development
12.9 Emerald Health Pharmaceuticals
12.9.1 Emerald Health Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Scleroderma Therapeutics Introduction
12.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2014-2019)
12.9.5 Emerald Health Pharmaceuticals Recent Development
12.10 Kadmon Holdings, Inc.
12.10.1 Kadmon Holdings, Inc. Company Details
12.10.2 Company Description and Business Overview
12.10.3 Scleroderma Therapeutics Introduction
12.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2014-2019)
12.10.5 Kadmon Holdings, Inc. Recent Development
12.11 Seattle Genetics, Inc.
12.12 Cytori Therapeutics, Inc.
12.13 Fibrocell Science, Inc.
12.14 Chemomab
12.15 Corbus Pharmaceuticals Holdings, Inc.
12.16 Genkyotex

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Scleroderma Therapeutics Key Market Segments
Table Key Players Scleroderma Therapeutics Covered
Table Global Scleroderma Therapeutics Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Immunosuppressors Figures
Table Key Players of Immunosuppressors
Figuer Phosphodiesterase 5 Inhibitors - PHA Figures
Table Key Players of Phosphodiesterase 5 Inhibitors - PHA
Figuer Endothelin Receptor Antagonists Figures
Table Key Players of Endothelin Receptor Antagonists
Figuer Prostacyclin Analogues Figures
Table Key Players of Prostacyclin Analogues
Figuer Calcium Channel Blockers Figures
Table Key Players of Calcium Channel Blockers
Figuer Analgesics Figures
Table Key Players of Analgesics
Figuer Others Figures
Table Key Players of Others
Table Global Scleroderma Therapeutics Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Scleroderma Therapeutics Market Share by Application in 2018 & 2025
Figure Systemic Case Studies
Figure Localized Case Studies
Figure Scleroderma Therapeutics Report Years Considered
Figure Global Scleroderma Therapeutics Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Size by Regions 2019-2025 (Million US$)
Table Global Scleroderma Therapeutics Market Share by Regions 2014-2019
Figure Global Scleroderma Therapeutics Market Share by Regions 2014-2019
Figure Global Scleroderma Therapeutics Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Scleroderma Therapeutics Revenue by by Players (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Share by by Players (2014-2019)
Figure Global Scleroderma Therapeutics Market Share by by Players in 2018
Table Global Scleroderma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Scleroderma Therapeutics Product/Solution/Service
Table Date of Enter into Scleroderma Therapeutics Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Scleroderma Therapeutics Market Size by Type (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Size Share by Type (2014-2019)
Figure Global Scleroderma Therapeutics Market Size Market Share by Type (2014-2019)
Table Global Scleroderma Therapeutics Market Size by Application (2014-2019) (Million US$)
Table Global Scleroderma Therapeutics Market Size Share by Application (2014-2019)
Figure Global Scleroderma Therapeutics Market Size Market Share by Application (2014-2019)
Figure Global Scleroderma Therapeutics Revenue Market Share by Application in 2018
Figure North America Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table North America Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table North America Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table North America Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table North America Scleroderma Therapeutics Market Share by Type 2014-2019
Table North America Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table North America Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Europe Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Europe Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Europe Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Europe Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Europe Scleroderma Therapeutics Market Share by Type 2014-2019
Table Europe Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Europe Scleroderma Therapeutics Market Share by Application 2014-2019
Figure China Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table China Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table China Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table China Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table China Scleroderma Therapeutics Market Share by Type 2014-2019
Table China Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table China Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Japan Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Japan Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Japan Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Japan Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Japan Scleroderma Therapeutics Market Share by Type 2014-2019
Table Japan Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Japan Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Southeast Asia Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Southeast Asia Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Scleroderma Therapeutics Market Share by Type 2014-2019
Table Southeast Asia Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Scleroderma Therapeutics Market Share by Application 2014-2019
Figure India Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table India Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table India Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table India Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table India Scleroderma Therapeutics Market Share by Type 2014-2019
Table India Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table India Scleroderma Therapeutics Market Share by Application 2014-2019
Figure Central & South America Scleroderma Therapeutics Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Scleroderma Therapeutics Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Scleroderma Therapeutics Market Share (2018-2019)
Table Central & South America Scleroderma Therapeutics Market Size by Type 2014-2019 (Million US$)
Table Central & South America Scleroderma Therapeutics Market Share by Type 2014-2019
Table Central & South America Scleroderma Therapeutics Market Size by Application 2014-2019 (Million US$)
Table Central & South America Scleroderma Therapeutics Market Share by Application 2014-2019
Table F. Hoffmann-La Roche AG Company Details
Table F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table F. Hoffmann-La Roche AG Recent Development
Table Bristol-Myers Squibb Company Company Details
Table Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Bristol-Myers Squibb Company Recent Development
Table Celgene Corporation Company Details
Table Celgene Corporation Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Celgene Corporation Recent Development
Table Argentis Pharmaceuticals, LLC Company Details
Table Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Argentis Pharmaceuticals, LLC Recent Development
Table Bayer AG Company Details
Table Bayer AG Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Bayer AG Recent Development
Table Boehringer Ingelheim International GmbH Company Details
Table Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Boehringer Ingelheim International GmbH Recent Development
Table Akashi Therapeutics Company Details
Table Akashi Therapeutics Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Akashi Therapeutics Recent Development
Table Prometic Life Sciences, Inc. Company Details
Table Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Prometic Life Sciences, Inc. Recent Development
Table Emerald Health Pharmaceuticals Company Details
Table Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Emerald Health Pharmaceuticals Recent Development
Table Kadmon Holdings, Inc. Company Details
Table Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business 2014-2019 (Million US$)
Figure Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2014-2019)
Table Kadmon Holdings, Inc. Recent Development
Table Seattle Genetics, Inc. Company Details
Table Cytori Therapeutics, Inc. Company Details
Table Fibrocell Science, Inc. Company Details
Table Chemomab Company Details
Table Corbus Pharmaceuticals Holdings, Inc. Company Details
Table Genkyotex Company Details
Table Global Scleroderma Therapeutics Market Size by Regions (Million US$) 2019-2025
Figure Global Scleroderma Therapeutics Market Size Share by Regions (2019-2025)
Figure Global Scleroderma Therapeutics Market Size Share by Regions in 2025
Figure North America Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Europe Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure China Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Japan Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure India Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Scleroderma Therapeutics Market Size Forecast (2019-2025)(Million USD)
Table Global Scleroderma Therapeutics Market Size by Product (2019-2025) (Million US$)
Figure Global Scleroderma Therapeutics Market Size by Product (2019-2025)
Figure Global Scleroderma Therapeutics Market Size by Product in 2025
Table Global Scleroderma Therapeutics Market Size by Application (2019-2025) (Million US$)
Figure Global Scleroderma Therapeutics Market Size by Application (2019-2025)
Figure Global Scleroderma Therapeutics Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

F. Hoffmann-La Roche AG、Bristol-Myers Squibb Company、Celgene Corporation、Argentis Pharmaceuticals, LLC、Bayer AG、Boehringer Ingelheim International GmbH、Akashi Therapeutics、Prometic Life Sciences, Inc.、Emerald Health Pharmaceuticals、Kadmon Holdings, Inc.、Seattle Genetics, Inc.、Cytori Therapeutics, Inc.、Fibrocell Science, Inc.、Chemomab、Corbus Pharmaceuticals Holdings, Inc.、Genkyotex

★調査レポート[強皮症治療薬の世界市場：規模・現状・予測2019-2025] (コード：DATA909X18941)販売に関する免責事項を必ずご確認ください。
★調査レポート[強皮症治療薬の世界市場：規模・現状・予測2019-2025]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • アテローム性動脈硬化症治療薬の世界市場：規模・現状・予測2019-2025
    DATA909X18181 / QYResearch / 2019年11月25日 / ※当調査レポートでは、アテローム性動脈硬化症治療薬の世界市場について調査・分析し、アテローム性動脈硬化症治療薬の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（小分子、生物製剤）、用途別（病院、クリニック、研究所、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界のアテローム性動脈硬化症治療薬市場動向 ・主要企業別マーケットシェア ・アテローム性動脈硬化症治療薬の種類別市場規模2014-2019 （小分子、生物製剤） ・アテローム性動脈硬化症治療薬の用途別市場規模2014-2019 （病院、クリニック、研究所、その他） ・アテローム性動脈硬化症治療薬の北米市場：主要企業・種類別/用途別市場規模 ・アテローム性動脈硬化症治療薬のヨーロッパ市場：主要企業・種類別/用途別市場規模...Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on...
  • 脾腫治療法の世界市場：規模・現状・予測2019-2025
    DATA909X18996 / QYResearch / 2019年11月25日 / ※当調査レポートでは、脾腫治療法の世界市場について調査・分析し、脾腫治療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（薬物療法、予防接種、その他）、用途別（正常（脾腫ではない）、中程度の脾腫、重度の脾腫）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の脾腫治療法市場動向 ・主要企業別マーケットシェア ・脾腫治療法の種類別市場規模2014-2019 （薬物療法、予防接種、その他） ・脾腫治療法の用途別市場規模2014-2019 （正常（脾腫ではない）、中程度の脾腫、重度の脾腫） ・脾腫治療法の北米市場：主要企業・種類別/用途別市場規模 ・脾腫治療法のヨーロッパ市場：主要企業・種類別/用途別市場規模...Splenomegaly is an enlargement of the spleen.The spleen usually lies in the left upper quadrant (LUQ) of the human abdomen. Splenomegaly is one of the four cardinal signs of hypersplenism which include: some reduction in number of circulating blood cells affecting granulocytes, erythrocytes or platelets in any combination; a compensatory proliferative response in the bone marrow; and the potential for correction of these abnormalities by splenectomy. The increasing demand for targeted therapy is one of the critical reasons that will drive splenomegaly therapeutics market growth. Targeted therapy is a novel approach used to treat malignancies without harming the peripheral healthy...
  • 悪性神経膠腫治療法の世界市場：規模・現状・予測2019-2025
    DATA909X18662 / QYResearch / 2019年11月25日 / ※当調査レポートでは、悪性神経膠腫治療法の世界市場について調査・分析し、悪性神経膠腫治療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（化学療法、放射線療法、標的療法）、用途別（大人、子供）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の悪性神経膠腫治療法市場動向 ・主要企業別マーケットシェア ・悪性神経膠腫治療法の種類別市場規模2014-2019 （化学療法、放射線療法、標的療法） ・悪性神経膠腫治療法の用途別市場規模2014-2019 （大人、子供） ・悪性神経膠腫治療法の北米市場：主要企業・種類別/用途別市場規模 ・悪性神経膠腫治療法のヨーロッパ市場：主要企業・種類別/用途別市場規模...Malignant glioma, a tumor derived from the nerve epithelium, is generally referred to as glioma, accounting for 40-50% of brain tumors, and is the most common intracranial malignant tumor.In 2018, the global Malignant Glioma Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Malignant Glioma Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Malignant Glioma Therapeutics development in North America, Europe and Asia-Pacific. The key...
  • 黒色腫診断及び治療の世界市場：規模・現状・予測2019-2025
    DATA909X18693 / QYResearch / 2019年11月25日 / ※当調査レポートでは、黒色腫診断及び治療の世界市場について調査・分析し、黒色腫診断及び治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（結節性黒色腫、表在性悪性黒色腫、メラニン性黒色腫、その他）、用途別（病院、診断センター、医療機関、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の黒色腫診断及び治療市場動向 ・主要企業別マーケットシェア ・黒色腫診断及び治療の種類別市場規模2014-2019 （結節性黒色腫、表在性悪性黒色腫、メラニン性黒色腫、その他） ・黒色腫診断及び治療の用途別市場規模2014-2019 （病院、診断センター、医療機関、その他） ・黒色腫診断及び治療の北米市場：主要企業・種類別/用途別市場規模 ・黒色腫診断及び治療のヨーロッパ市場：主要企業・種類別/用途別市場規模...Melanoma is one of the serious types of skin cancer that develops from pigment-containing cells called melanocytes. The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities.In 2018, the global Melanoma Diagnostics and Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Melanoma Diagnostics and Therapeutics status, future forecast, growth opportunity, key market and key players. The study...

    • ◆H&Iグローバルリサーチのお客様（例）◆